CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-terf-butylbenzyl)- (pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin e2 agonist: Characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance

Drug Metabolism and Disposition

Volumn 36, Issue 10, 2008, Pages 2093-2103

  Prakash, Chandra ^a,b   Wang, Weiwei ^a   O'Connell, Thomas ^a   Johnson, Kim A ^a  

^a PFIZER INC   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[3 [[(4 TERT BUTYLBENZYL)(3 PYRIDINESULFONYL)AMINO]METHYL]PHENOXY]ACETIC ACID; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; KETOCONAZOLE; QUERCETIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEALKYLATION; DECARBOXYLATION; DEMETHYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; FEMALE; FRACTURE HEALING; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DINOPROSTONE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; METHYLATION; MICROSOMES, LIVER; MIDDLE AGED; PYRIDINES; RECEPTORS, PROSTAGLANDIN E;

EID: 52949134764     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022897     Document Type: Article

References (29)

1. Bachmann KA and Ghosh R (2001) The use of in vitro methods to predict in vivo pharmaco-kinetics and drug interactions. Curr Drug Metab 3:299-314.
2. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
3. Baranczewski P, Stańczak A, Kautiainen A, Sandin P, and Edlund PO (2006) Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 58:341-352.
4. Breyer RM, Bagdassarian CK, Myers SA, and Breyer MD (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41:661-690.
5. Caldwell J (1996) The role of drug metabolism studies for efficient drug discovery and development: opportunities to enhance time- and cost-efficiency. J Pharm Sci 2:117-119.
6. Carlin JR, Christofalo P, Arison BH, Ellsworth RE, Rosegay A, Miller RR, Chiu SH, and VandenHeuvel WJ (1997) Disposition and metabolism of finasteride in dogs. Drug Metab Dispos 25:100-109.
7. Emoto C and Iwasaki K (2006) Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 36:219-233.
8. Gaylor JL and Mason HS (1968) Investigation of the component reactions of oxidative sterol demethylation. Evidence against participation of cytochrome P450. J Biol Chem 243:4966-4972.
9. Johnson KA and Prakash C (2005) Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl-(pyridine-3-sulfonyl)-amino]- methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats. Drug Metab Dispos 33:1191-1201.
10. Kamel A and Prakash C (2006) High performance liquid chromatography/ atmospheric pressure ionization/tandem mass spectrometry (HPLC/API/MS/MS) in drug metabolism and toxicology. Curr Drug Metab 7:837-852.
11. Kamm JJ and Szuna A (1973) Studies on an unusual N-dealkylation reaction. II. Characteristics of the enzyme system and a proposed pathway for the reaction. J Pharmacol Exp Ther 184:729-738.
12. Khojasteh-Bakht SC, Rossulek M, Fouda HG, and Prakash C (2003) Identification of the human cytochrome P450 isoform(s) responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543. Xenobiotica 33:1201-1210.
13. Kostiainen R, Kotiaho T, Kuuranne T, and Auriola S (2003) Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J Mass Spectrom 38:357-372.
14. Kulanthaivel P, Barbuch RJ, Davidson RS, Yi P, Rener GA, Mattiuz EL, Hadden CE, Goodwin LA, and Ehlhardt WJ (2004) Selective reduction of N-oxides to amines: application to drug metabolism. Drug Metab Dispos 32:966-972.
15. Miller WL and Gaylor JL (1970) Investigation of the component reactions of oxidative sterol demethylation. Oxidation of a 4,4-dimethyl sterol to a 4-β-rnethyl-4α-carboxylic acid during cholesterol biosynthesis. J Biol Chem 245:5375-5381.
16. Omura T and Sato R (1964) The carbon monoxide binding pigment of liver microsomes. I. Evidence of its hemoprotein nature. J Biol Chem 239:2370-2378.
17. 2 agonist induces bone healing. Proc Nat Acad Sci U S A 100:6736-6740.
18. Parkinson A (2001) Biotransformation of xenobiotics, in Casarett and Doul's Toxicology: The Basic Science of Poisons (Klaassen CD ed) pp 133-224, McGraw-Hill, New York.
19. Prakash C, Kamel A, Cui D, Whalen R, Miceli J, and Tweedie D (2000) Identification of the major human liver cytochrome P450 isoform responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 49 (Suppl 1):35S-42S.
20. Prakash C, Kamel A, Gummerus J, and Wilner K (1997) Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos 25:863-872.
21. Prakash C, Lin J, Colizza K, and Miao Z (2007a) Characterization of metabolites of a NK1 receptor antagonist, CJ-11,972, in human liver microsomes and recombinant human CYP isoforms by liquid chromatography/tandem mass spectrometry. Rapid Comm Mass Spectrom 21:2822-2832.
22. Prakash C, Shaffer CL, and Nedderman A (2007b) Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340-369.
23. Roberts ES, Vaz AD, and Coon MJ (1991) Catalysis by cytochrome P-450 of an oxidative reaction in xenobiotic aldehyde metabolism: deformylation with olefin formation. Proc Natl Acad Sci USA 88:8963-8966.
24. Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS, and Estabrook RW (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos 23:765-775.
25. Testino SA Jr and Patonay G (2003) High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 30:1459-1467.
26. Vaz AD (2001) Multiple oxidants in cytochrome P450 catalyzed reactions: implications for drug metabolism. Curr Drug Metab 2:1-16.
27. Watt AP, Mortishire-Smith RJ, Gerhard U, and Thomas SR (2003) Metabolite identification in drug discovery. Curr Opin Drug Discov Devel 6:57-65.
28. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891.
29. Yoo HH, Chung HJ, Lee J, Lee CS, Kang MJ, and Kim DH (2008) Enzymatic C-demethylation of 1-[2-(5-tert-butyl-[1,3,4]oxadiazole-2-carbonyl)-4-fluoro- pyrrolidin-1-yl]-2-(2-hydroxy-1,1-dimethyl-ethylamino)ethanone (LC15-0133) in rat liver microsomes. Drug Metab Dispos 36:485-489.